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Background: Acute cough is one of the most frequent symptoms prompting a visit to a health care provider,
usually following a viral upper respiratory tract infection (URTI). The disproportionate use of antibiotics in children
with URTIs, recently highlighted in the medical literature, could lead to associated side effects, without any
beneficial effect. Although an early, albeit inappropriate, antibiotic prescription increases parental satisfaction, URTIs
are predominantly viral infections and are generally self-limiting. Therefore the aim of this study was to analyze the
effectiveness of antibiotics compared to symptomatic drugs (central and peripheral antitussives) on URTI-related
cough in a pediatric population.
Methods: This is a prospective observational study of 330 children who required pediatric consultation for acute
cough. Severity, frequency and type of cough were assessed at baseline and after 6 days of treatment (antitussives
n = 123, antibiotics n = 89 or combination of them n = 38) or no treatment (n = 80). The outcome of cough
management after 6 days was analyzed in terms of resolution, improvement, no change or worsening of
symptoms. Study assessments were performed using a standardized questionnaire administered to parents.
Results: Between children treated with antitussives or antibiotics, there was a statistically significant difference in
the resolution of cough. Moreover, if considering peripheral antitussives, the resolution of cough was significantly
higher with antitussives than with antibiotics (p < 0.01). There was no difference in cough resolution between
children treated with antitussives and those receiving a combination of antibiotics and antitussives, either central
and peripheral antitussives.
Conclusion: Antibiotics are generally not useful nor appropriate in treating acute cough due to the common cold.
Furthermore, inappropriate antibiotic use introduces the possibility of adverse side effects as well as promotion
of antibiotic resistance. The findings of the present study suggest that antitussives, especially peripherally acting
agents, represent an effective treatment option for acute pediatric cough caused by URTIs.
Keywords: Levodropropizine, Cough, Antibiotic, Antitussives, URTI, Children* Correspondence: alessandro.zanasi@aosp.bo.it
1Pneumology Unit, University of Bologna, S.Orsola Malpighi Hospital,
Bologna, Italy
Full list of author information is available at the end of the article
© 2016 Zanasi et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zanasi et al. Multidisciplinary Respiratory Medicine  (2016) 11:29 Page 2 of 6Background
Antibiotic resistance of pathogenic bacteria is being rec-
ognized as a major emerging threat in healthcare set-
tings throughout the world. In addition, the discovery of
new molecules with antimicrobial activity is no longer
keeping pace with the spread of resistant bacterial path-
ogens. Therefore local and international efforts and
strategies are needed to neutralize this emerging threat
[1]. The main contributor to the development, increase
and spread of antibiotic resistance is the overuse of anti-
biotics, particularly in children. Of particular concern is
the over-prescription of these drugs to children for the
treatment of upper respiratory infections (URTIs) and
influenza-like illness.
URTI, the most commonly treated acute problem in
primary care, is a pathological condition most often
caused by viruses [2, 3] and thus, does not require anti-
biotics [4−6]. However, URTIs are the conditions for
which the misuse of antibiotics is particularly high and
reported worldwide [7, 8] despite the strong evidence on
their self-limiting nature. Even some of the bacterial ill-
nesses (such as otitis media and sinusitis) are usually
self-limited and antibiotic treatment is not recom-
mended for these conditions [9].
An important factor leading to the inappropriate
use of antibiotics in children with URTIs is the diffi-
culty in making a reliable and rapid clinical diagno-
sis. In fact, distinguishing between the clinical
features of influenza and bacterial infections is the
main challenge for physicians. Furthermore, doctors
may prescribe antibiotics as a response to parents’
expectations. A survey of more than 600 pediatri-
cians showed that 96 % had been asked by parents
for antibiotics in circumstances for which they were
unnecessary [10].
URTI or common cold are by far the most common
cause of acute cough, defined as cough of recent
onset and lasting for a maximum of 3 weeks. For the
treatment of acute cough, symptomatic over-the-
counter (OTC) drugs, such as antitussive or mucoac-
tive drugs, are frequently recommended as a first-line
intervention [11].
Mainly, two classes of antitussive agents are available
for the treatment of cough in children: centrally acting
cough suppressants (codeine, dextromethorphan and
cloperastine), and peripherally acting antitussives such
as levodropropizine, a non-opioid inhibitor of the cough
reflex at the peripheral nerve level (sensory C fibres) and
a modulator of sensory neuropeptides within the respira-
tory tract [12]. Hence, in order to analyze the effective-
ness of antibiotics compared to symptomatic drugs in
improving or eliminating cough caused by URTI, we car-
ried out an analysis of data collected from a prospective
study comparing children, with URTI and cough, treatedwith antitussive drug as symptomatic therapy or antibi-
otics or their combination.
Methods
This study is an analysis of data collected during a pro-
spective observational study performed in 2012 [13]. It
was performed in children who required a pediatric con-
sultation for acute cough of recent onset (≤3 weeks)
caused by URTI, from 1st February to 30th April 2010.
Study assessments were performed through a stan-
dardized Pediatric Cough Questionnaire (PCQ) devel-
oped and approved by the Scientific Committee of the
Italian Society of Cough Study. The PCQ consists of two
different parts.
Baseline assessment regarding type (dry, productive,
mix), frequency, duration and severity of cough (defined
as: mild if it did not interfere with common daily activ-
ities, moderate if occasionally disturbed common daily
activities and severe if interfered with daily activities and
night rest) was performed during the first study visit by
the pediatrician, who interviewed parents and/or pa-
tients, compiled the first part of the PCQ and prescribed
the most appropriate treatment for cough.
The PCQ was given to the children’s parents to
complete the second part 6 days after the first study
visit, to document administered treatments and to self-
assess outcome of therapy in terms of resolution (cough
disappearance), improvement (just few sporadic cough
spells), no change in symptoms or worsening of cough
(more frequent and severe cough).
Patients presented 1 week after the first visit at which
time questionnaires were collected by the physician. Any
adverse events were also reported.
According to the aim of this study, questionnaires of
patients reported specific types of treatment; in particu-
lar, antibiotics or antitussives, combination of antibiotics
and antitussives, and no pharmacological treatment,
have been selected for analysis.
Statistics
Continuous variables are presented as mean +/− stand-
ard deviation. Categorical and discrete variables are pre-
sented as frequency and percentage. Differences between
groups were tested using χ2 test for categorical and
discrete variables (with Yates correction for 2x2 tables).
Analysis of variance (ANOVA) has been used to analyze
the differences between groups for the following two pa-
rameters: age (expressed as years) and duration of cough
(expressed as days).
The correlation between the treatment and the type of
cough (productive, mix or dry), the episodes of cough
(occasional, frequent or continuous) and the severity of
cough (mild, moderate, severe) was performed by the
polychotomous stepwise logistic regression.
Fig. 1 Types of treatments administered to children included in
the study
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Epidemiology of cough and clinical findings
In total, 330 children affected by URTI were evaluated in
this analysis. Clinical data including frequency, severity and
type of cough were recorded on the PCQ during the first
study visit. Tables 1 and 2 reported patients’ characteristics





Age (years), mean (min-max) 4.9 (0.4–13.0) 6.4 (0.8–14.0
Cough Duration (days), mean (min-max) 5.7 (1.0–21.0) 4.6 (2.0–20.0
Cough Type (%)
Productive 61.8 % 26 %
Dry 23.6 % 64.2 %
Mix 14.6 % 9.8 %
Cough Intensity (%)
Mild 19.1 % 10.6 %
Moderate 36 % 63.4 %
Severe 44.9 % 26 %
Cough Frequency (%)
Occasional 22.5 % 20.3 %
Frequent 58.4 % 71.5 %
Continuous 19.1 % 8.1 %
Concomitant respiratory diseases
Yes 74.2 % 72.4 %
No 25.8 % 27.6 %
First episode of cough
Yes 57.3 % 51.2 %
No 42.7 % 48.8 %Treatment of cough
Eighty-nine children (27 %) received antibiotics, while
38 (12 %) children received a combination of antibiotics
and antitussives; central antitussives (codeine or cloper-
astine) were given in 16 cases (5 %), and peripheral anti-
tussives (levodropropizine) were given to 22 children
(7 %). Forty-four and 79 children received central or per-
ipheral antitussives respectively (13 and 24 %), without
antibiotics. Eighty children (24 %) did not receive any
treatment for cough (Fig. 1).
Correlation between treatments outcomes and type of
treatment received
Fifty-one per cent of patients treated with antitussives
had an improvement in cough, 41 % reported resolution
of cough, and 7 % did not have any change (Fig. 2).
Among the patients receiving peripheral antitussives
(levodropropizine), 49 % reported improvement in cough,
and 47 % reported the resolution of cough. Four per cent
did not have any change in cough symptoms. In the group
of children receiving central antitussives, 54.5 % reported
improvement in cough, 29.5 % reported resolution of
cough, 14 % did not have any change in symptoms and






) 6.5 (1.7–13.3) 7.0 (0.3–14.0) p < 0.01
) 6.5 (2.0–30.0) 5.0 (2.0–1.0) p < 0.05
52.6 % 47.3 % p < 0.01
26.3 % 34.5 %
21.1 % 18.2 % NS ANT vs ATT,
NS ATT vs COM
0 % 43.6 % NS ANT vs ATT
34.2 % 54.5 % NS ANT vs ATT,
NS ATT vs COM
65.8 % 1.8 % NS ANT vs ATT
0 % 58.2 % NS ANT vs ATT
60.5 % 41.8 % NS ANT vs ATT,
NS ATT vs COM
39.5 % 0 % NS ANT vs ATT
81.6 % 92.7 % p < 0.05
18.4 % 7.3 %
63.2 % 40 % NS
36.8 % 60 % NS
Table 2 Cough characteristics at baseline according to types of
administered antitussives (centrals vs levodropropizine)
Central Antitussives
(CA) n = 44
Levodropropizine
(LDP) n = 79
p
Cough Type (%)
Productive 25 % 75 % 0,1773 (NS)
Dry 41.8 % 58.2 %
Mix 25 % 75 %%
Cough Intensity (%)
Mild 38.5 % 61.5 % 0.7517 (NS)
Moderate 33.3 % 66.7 %
Severe 40.6 % 59.4 %
Cough Frequency (%)
Occasional 24 % 76 % 0.3869 (NS)
Frequent 38.6 % 61.4 %
Continuous 40 % 60 %
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biotics and antitussives reported improvement in their
symptoms. The resolution of cough was reported in
37 % of children. Eight per cent of patients did not have
any change and 3 % reported worsening of their condi-
tion (Fig. 2).
Considering the patients treated with antibiotics
plus levodropropizine, 54.5 % noted improvement in
their symptoms and 45 % reported resolution of
cough. In the group of patients receiving both antibi-
otics and central antitussives, 50 % reported an im-
provement of symptoms, 25 % reported cough
resolution, 19 % did not have any change in cough
symptoms and 6 % worsened (Fig. 3).Fig. 2 Treatments outcomes according to different types of administered tConsidering patients treated with antibiotics, 63 %
reported an improvement, 24 % reported resolution of
cough and 13.5 % did not have any change (Fig. 2).
There was no statistically significant difference in the
resolution of cough between patients treated with anti-
tussives and those treated with the combination of anti-
tussives and antibiotics (χ2 = 0.053; p = NS).
Comparing children treated with antitussives or antibi-
otics, there was a statistically significant difference in the
resolution of cough (χ2 = 5.99; p < 0.05) in favor of anti-
tussive drugs.
Including in the analysis the distinction between cen-
tral and peripheral antitussives, the difference in the
resolution of cough between children treated with a per-
ipheral agent (levodropropizine) or antibiotics alone was
statistically significant (χ2 = 8.998; p < 0.01) in favor of
levodropropizine. This result did not change when
considering only children with severe cough at base-
line (χ2 = 8.928; p < 0.01). On the contrary, the reso-
lution of cough was not statistically different between
children treated with central antitussives or antibiotics
(χ2 = 0.280; p = NS).
All statistical analysis results are reported in Tables 3
and 4.
Discussion
An interventional strategy is necessary to reduce anti-
biotic misuse and overuse in pediatric primary care for
the treatment of acute cough, including the promotion
of other beneficial approaches, such as medications for
the amelioration of troublesome symptoms associated
with URTI. The use of antibiotics in pediatric URTI
remains controversial, despite evidence that the vastreatment
Fig. 3 Treatments outcomes according to different types of treatment including the distinction between central and peripheral antitussive molecules
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URTIs are caused by bacteria, the probability of their
resolution without the administration of antibiotics is
high [14]. Since cough is usually the major cause of
discomfort in patients presenting with URTI, a symp-
tomatic treatment with antitussive drugs appears to
be a reasonable approach to the management of this
condition [9].
Nonetheless, from the analysis of questionnaires we
found that in the group of children receiving a pharma-
cological treatment (76 %) for their URTI symptoms,
half were prescribed antibiotics with or without antitus-
sive drugs while the remaining 38.5 % were treated with
peripheral or central antitussives.
One important and clinically relevant finding of our
study is that there was no statistically significant differ-
ence in the percentage of cough resolution between chil-
dren treated with antitussive compared to children
receiving a combination of antibiotics and antitussives.
Furthermore, cough resolution in children treated with
antitussives was significantly higher than in childrenTable 3 Outcome differences between group of treatment: χ2
test results
Treatments Resolution of cough
Antibiotics vs antitussives χ2 = 5.999 (p < 0.05)
Antibiotics vs peripheral antitussives χ2 = 8.998 (p < 0.01)
Antibiotics vs central antitussives χ2 = 0.280 (p = NS)
Antibiotics + antitussives vs antitussives χ2 = 0.053 (p = NS)
Antibiotics + peripheral antituss.
vs peripheral antitussives
χ2 = 0.016 (p = NS)
Antibiotics + central antitussives
vs central antitussives
χ2 = 0.001 (p = NS)treated with antibiotics. We also observed that after a
week of treatment, levodropropizine significantly solved
cough greater than antibiotics did.
Furthermore, this result did not change when consid-
ering only children with severe cough at baseline.
Taken together, these findings confirm that the use of
antibiotics is of little benefit and it may be not necessary
in the symptomatic management of cough associated
with URTI, consistent with a previous report [15] in
which the management of acute moist cough in the
presence of URTI by means of antimicrobial therapy was
not superior to the treatment with inhaled mucoactive
drugs in the pediatric setting.
The main limitation of our study is its observational
design, thus lacking treatment randomization, blinding
of both patients and outcome assessors, and homo-
geneity in groups for treatment at baseline. However,
we wanted to evaluate in a real-life pediatric setting
the management of acute cough associated with
URTI, comparing also the efficacy of the two mainTable 4 Outcome differences between group of treatment in
children with severe cough: χ2 test results
Treatments Resolution of cough
Antibiotics vs antitussives χ2 = 3.738 (p = 0.0532, NS)
Antibiotics vs peripheral antitussives χ2 = 8.928 (p < 0.01)
Antibiotics vs central antitussives χ2 = 0.000 (p = NS)
Antibiotics + antitussives vs antitussives χ2 = 0.218 (p = NS)
Antibiotics + peripheral antituss.
vs peripheral antitussives
χ2 = 0.000 (p = NS)
Antibiotics + central antitussives
vs central antitussives
χ2 = 0.713 (p = NS)
NA not applicable
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vs antitussive therapy.
Finally, another possible limitation is the lack of a
microbiological characterization of the URTI. Nonethe-
less, in the presence of URTI, guidelines for the manage-
ment of cough in children do not recommend
microbiological testing [15, 16] but rather, a strategy of
no antibiotic or delayed antibiotic prescription, is recom-
mended [15, 17].
Conclusion
Our observational results suggest that acute cough asso-
ciated with URTI can be effectively managed with symp-
tomatic therapy alone, i.e., central or peripheral
antitussives, yielding the same clinical benefits compared
with combination therapy that included antibiotics. the
present study, levodropropizine appeared to be the most
effective option at relieving cough. In light of previously
demonstrated efficacy data [12, 18, 19] and the consider-
able safety profile of levodropropizine [18, 20], these
results further support its use for the management of
acute pediatric cough associated with URTI. Further
large randomized clinical trial in children should be
conducted in order to confirm the effectiveness of anti-
tussive drugs used in this observational study.
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